在重症儿童中开发人口药动力学模型的设计优化:适用于茶叶,皮皮拉西林和美罗
Gastón García-Orueta1, Laura Butragueño-Laiseca2,3,4,5, María José Santiago2,3,4,5
1Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.
Clinical pharmacokinetics
|November 29, 2025
概括
优化对小儿群体药动力学 (popPK) 模型的研究设计,对抗生素如泰克托普拉宁,皮佩拉西林和梅罗显著提高模型的精度. 这种方法减少了所需的血液样本数量,最大限度地降低了重症监护机构的患者负担和成本.
科学领域:
- 药理动力学和药理动力学
- 儿科药理学 儿科药理学
- 临床试验设计 临床试验设计
背景情况:
- 种群药动力学 (popPK) 模型对于优化儿科药物剂量至关重要.
- 现有的研究设计往往缺乏效率,由于儿科患者人数有限和资源稀缺,造成了挑战.
- 需要提高popPK模型的精度,同时尽量减少患者的负担和成本.
研究的目的:
- 优化研究设计,以开发小儿病人的teicoplanin,piperacillin和meropenem的popPK模型.
- 提高模型精度,降低患者负担和经济成本.
- 评估针对患有或没有连续脏替代疗法 (CKRT) 的儿科患者的设计.
主要方法:
- 使用了NONMEM 7.5.5中的$DESIGN选项来优化费舍尔信息矩阵 (FIM).
- 为每个抗生素选择先前开发的popPK模型.
- 确定受试者数量为28人 (14人使用CKRT,14人不使用CKRT),并分析不同样本类型 (血,预过器,后过器,废水).
主要成果:
- 优化的设计要求每个人采样的次数更少:3次是提科普拉宁,4次是皮佩拉西林,6次是梅罗.
- 与原始研究相比,每名患者的总样本减少了25% (泰科普拉宁),51% (皮皮拉西林) 和21% (梅罗).
- 优化的设计在不同比例的CKRT/无CKRT患者和不同协变值中表现出稳健性.
结论:
- 优化研究设计可以提高popPK模型参数的准确性和精度.
- 减少采样要求提供了显著的优势,特别是对于重症儿科患者.
- 有效的研究设计对于在有限的资源下推进儿科药物治疗至关重要.
相关概念视频
01:12Analysis of Population Pharmacokinetic Data
643
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
643
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
188
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
188
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
231
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
231
01:26Pharmacokinetic Models: Comparison and Selection Criterion
301
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
301
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
165
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
165
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
219
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
219